A Phase 2 clinical trial testing PIPE-307, an experimental therapy designed to support myelin repair in people with multiple sclerosis (MS), has failed to meet its primary or secondary efficacy goals. The U.S.-based VISTA trial (NCT06083753) enrolled more than 180 adults with relapsing-remitting MS (RRMS). Participants received one of two PIPE-307 doses or a placebo […]
The post New MS experimental therapy misses main goals in clinical trial appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com